ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 84 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2014. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $351,000 | -12.7% | 252,516 | 0.0% | 0.00% | -50.0% |
Q1 2023 | $402,000 | -54.8% | 252,516 | +76.9% | 0.00% | -50.0% |
Q4 2022 | $889,000 | -21.3% | 142,722 | -15.3% | 0.00% | -20.0% |
Q3 2022 | $1,129,000 | +5.3% | 168,552 | 0.0% | 0.01% | 0.0% |
Q2 2022 | $1,072,000 | +37.1% | 168,552 | 0.0% | 0.01% | +66.7% |
Q1 2022 | $782,000 | -7.2% | 168,552 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $843,000 | +26.4% | 168,552 | +204.6% | 0.00% | +50.0% |
Q3 2021 | $667,000 | -43.0% | 55,338 | 0.0% | 0.00% | -50.0% |
Q2 2021 | $1,170,000 | -24.6% | 55,338 | 0.0% | 0.00% | -33.3% |
Q1 2021 | $1,552,000 | +7.9% | 55,338 | 0.0% | 0.01% | 0.0% |
Q4 2020 | $1,439,000 | -2.7% | 55,338 | +39.1% | 0.01% | -25.0% |
Q3 2020 | $1,479,000 | +47.6% | 39,784 | +103.6% | 0.01% | +33.3% |
Q2 2020 | $1,002,000 | +62.7% | 19,537 | 0.0% | 0.01% | +50.0% |
Q1 2020 | $616,000 | -44.3% | 19,537 | +5.3% | 0.00% | -33.3% |
Q4 2019 | $1,106,000 | +62.6% | 18,554 | 0.0% | 0.01% | +50.0% |
Q3 2019 | $680,000 | -21.2% | 18,554 | 0.0% | 0.00% | -20.0% |
Q2 2019 | $863,000 | +5.8% | 18,554 | -8.8% | 0.01% | +25.0% |
Q1 2019 | $816,000 | -12.7% | 20,334 | 0.0% | 0.00% | -20.0% |
Q4 2018 | $935,000 | +3.7% | 20,334 | 0.0% | 0.01% | +25.0% |
Q3 2018 | $902,000 | -4.3% | 20,334 | -15.5% | 0.00% | -20.0% |
Q2 2018 | $943,000 | -55.7% | 24,064 | -18.2% | 0.01% | -54.5% |
Q1 2018 | $2,127,000 | +9.3% | 29,412 | -0.5% | 0.01% | +10.0% |
Q4 2017 | $1,946,000 | +31.4% | 29,555 | 0.0% | 0.01% | +25.0% |
Q3 2017 | $1,481,000 | -45.9% | 29,555 | -50.0% | 0.01% | 0.0% |
Q2 2017 | $2,736,000 | +162.1% | 59,110 | +100.0% | 0.01% | +33.3% |
Q1 2017 | $1,044,000 | +56.8% | 29,555 | 0.0% | 0.01% | +50.0% |
Q4 2016 | $666,000 | +223.3% | 29,555 | +98.2% | 0.00% | +300.0% |
Q3 2016 | $206,000 | +40.1% | 14,909 | 0.0% | 0.00% | 0.0% |
Q2 2016 | $147,000 | -66.4% | 14,909 | -42.4% | 0.00% | -66.7% |
Q1 2016 | $438,000 | -18.0% | 25,876 | +7.9% | 0.00% | 0.0% |
Q4 2015 | $534,000 | -5.7% | 23,991 | 0.0% | 0.00% | -25.0% |
Q3 2015 | $566,000 | -71.2% | 23,991 | 0.0% | 0.00% | -63.6% |
Q2 2015 | $1,962,000 | -16.9% | 23,991 | -5.9% | 0.01% | -21.4% |
Q1 2015 | $2,361,000 | +78.3% | 25,501 | -22.1% | 0.01% | +75.0% |
Q4 2014 | $1,324,000 | +234.3% | 32,736 | +102.2% | 0.01% | +300.0% |
Q3 2014 | $396,000 | +54.7% | 16,192 | 0.0% | 0.00% | +100.0% |
Q2 2014 | $256,000 | +4.5% | 16,192 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $245,000 | -2.0% | 16,192 | -11.1% | 0.00% | 0.0% |
Q4 2013 | $250,000 | +32.3% | 18,214 | +82.1% | 0.00% | 0.0% |
Q3 2013 | $189,000 | – | 10,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |